56 filings
8-K
AKCA
Akcea Therapeutics, Inc.
13 Oct 20
Entry into a Material Definitive Agreement
8:46am
8-K
AKCA
Akcea Therapeutics, Inc.
31 Aug 20
Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics
5:16pm
8-K
AKCA
Akcea Therapeutics, Inc.
4 Aug 20
Akcea Reports Financial Results and Highlights for Second Quarter 2020
4:18pm
8-K
AKCA
Akcea Therapeutics, Inc.
9 Jul 20
Akcea Announces Appointment of New Chief Medical Officer
7:30am
8-K
AKCA
Akcea Therapeutics, Inc.
19 Jun 20
Departure of Directors or Certain Officers
4:30pm
8-K
txv9n5 z8ervo
18 May 20
Akcea Announces Appointment of New Chief Financial Officer
7:30am
8-K
lcm7k1f9o
5 May 20
Akcea Reports Financial Results and Highlights for First Quarter 2020
4:16pm
8-K
mnyuvs 9sbmno
29 Apr 20
Departure of Directors or Certain Officers
4:30pm
8-K
pnv7 0p7f21ebg
9 Apr 20
Entry into a Material Definitive Agreement
7:00am
8-K
prz42 sefp5bh94qosr
24 Mar 20
Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
7:37am
8-K
zzv0hwj 8xevxanhdm4
20 Mar 20
Entry into a Material Definitive Agreement
4:18pm
8-K
ebb8nc9jqk5okn1f
11 Mar 20
Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy
7:30am
8-K
b2lis52pl
4 Mar 20
Departure of Directors or Certain Officers
4:40pm
8-K
tuzcs2ywdem9izxawh
25 Feb 20
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
4:16pm
8-K
tcqj9vf 4nqkgrdr3n
13 Feb 20
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
7:30am
8-K
90827eo6 s2wyo175f
28 Jan 20
Akcea and Ionis report positive topline phase 2 study results of
4:31pm
8-K
689lz
22 Jan 20
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-LRX
7:30am
8-K
7fext4a joe872fk
10 Jan 20
Entry into a Material Definitive Agreement
4:16pm
8-K
ki4gj2qhndqpdak8
6 Jan 20
Departure of Directors or Certain Officers
7:00am
8-K
drnqafemj
19 Dec 19
Other Events
7:00am